Study in Patients With Solid Tumor Regarding Access to Dermo-cosmetics and Aesthetic Solutions

Neoplasms Clinical Trial

— DERMOCOS  

Official title:

Study in Patients With Solid Tumor Regarding Access to Dermo-cosmetics and Aesthetic Solutions

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05907551
• Other study ID #: 2023-001
• Secondary ID: 2023-A00546-39
• Status: Recruiting
• Start date: July 25, 2023
• Est. completion date: October 25, 2023

Study information

• Verified date: August 2023
• Source: Institut de cancérologie Strasbourg Europe
• Contact: Manon VOEGELIN
• Phone: (0)3 68 33 95 23
• Email: promotion-rc[@]icans.eu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Cancer treatments can trigger cutaneous side-effects, as well as nail and hair toxicities. When related to drug treatment, this iatrogeny depends on the type of drug, its dosage and individual susceptibility. Although these dermatological adverse events are rarely serious, they can significantly alter patients' quality of life, and may even necessitate the introduction of curative treatment.

The impact of these side effects can be mitigated by the use of dermo-cosmetic products and aesthetic solutions. However, most of this supportive care is not reimbursed by the health insurance system, representing a source of inequalities in access to healthcare for cancer patients.

Description:

This study aims at establishing, in a cohort of patients with solid tumors, the state of their knowledges, given information and their financial capacities regarding access to dermo-cosmetics and aesthetic solutions, that are used in the attenuation of cancer treatments' side-effects.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 210
• Est. completion date: October 25, 2023
• Est. primary completion date: October 25, 2023
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age > 18 years

• Patients with solid tumors (eligible localization include: digestive system, Head and Neck, Breast, Brain, Lung Tumors, Urological and Gynecologic cancers)

• Patients able to read and understand French

• Patients that has expressed their consent and with signed consent form

Exclusion Criteria:

• Minor or patients placed under guardianship or supervision

• Patients unable to read French

• Patients placed under judicial protection

Related Conditions & MeSH terms

• Neoplasms

Intervention

Other:
• Questionnaires
25-items questionnaire

Locations

Country	Name	City	State
France	Institut de cancérologie Strasbourg Europe	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
Institut de cancérologie Strasbourg Europe

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Describe patients' knowledges regarding cutaneous side-effects, nail and hair toxicities induced by anticancer drugs	4 items questionnaires	at inclusion
Primary	Describe patients' knowledges regarding dermo-cosmetics and aesthetic solutions that can attenuate cutaneous side-effects, nail and hair toxicities induced by anticancer drugs	10 items questionnaires	at inclusion
Secondary	Describe patients' socio-economic profile to assess equity regarding access to dermo-cosmetics and aesthetic solutions	11 items questionnaires	at inclusion
Secondary	Correlate patients' knowledge level depending on tumoral location	Tumoral location as described in medical chart	at inclusion
Secondary	Correlate patients' knowledge level depending on received treatment	Type of chemotherapy administered on the day of inclusion as described in medical chart	at inclusion
Secondary	Correlate patients' knowledge level depending on treatment phase	Type of treatment phase (i.e. neoadjuvant, adjuvant, 1st or 2nd metastatic line) as described in medical chart	at inclusion